What's in AdventHealth's pipeline?

AdventHealth has 11 drugs in our index: 8 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 2 in Phase 1.

Which companies overlap with AdventHealth's portfolio?

Top competitors by shared drug class: Ajay Wasan, MD, Msc, Alza Corporation, DE, USA, Archimedes Development Ltd, Asbjørn Mohr Drewes, Bezmialem Vakif University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/adventhealth.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

AdventHealth — Portfolio Competitive Intelligence Brief

AdventHealth pipeline: 8 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 0 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Preop orphenadrine IV	Preop orphenadrine IV	marketed
Postop oral oxycodone & acetaminophen	Postop oral oxycodone & acetaminophen	marketed
Postop hydromorphone IV	Postop hydromorphone IV	marketed	Opioid analgesic	Mu-opioid receptor (OPRM1)	Pain Management
Postop oral orphenadrine	Postop oral orphenadrine	marketed	Anticholinergic muscle relaxant	Muscarinic acetylcholine receptors	Pain Management / Musculoskeletal
Postop orphenadrine IV	Postop orphenadrine IV	marketed	Anticholinergic agent / Muscle relaxant	Muscarinic acetylcholine receptors	Pain Management / Anesthesia
Postop acetaminophen IV	Postop acetaminophen IV	marketed	Non-opioid analgesic; antipyretic	Cyclooxygenase (COX) enzymes	Pain Management
Postop oral oxycodone	Postop oral oxycodone	marketed	Opioid analgesic	Mu (μ) opioid receptor	Pain Management
Preop acetaminophen IV	Preop acetaminophen IV	marketed	Analgesic and antipyretic (non-NSAID)	Cyclooxygenase (COX) enzymes	Pain Management

Therapeutic area mix

Pain Management · 4
Pain Management / Anesthesia · 1
Pain Management / Musculoskeletal · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ajay Wasan, MD, Msc · 1 shared drug class
Alza Corporation, DE, USA · 1 shared drug class
Archimedes Development Ltd · 1 shared drug class
Asbjørn Mohr Drewes · 1 shared drug class
Bezmialem Vakif University · 1 shared drug class
BioDelivery Sciences International · 1 shared drug class
Boston Children's Hospital · 1 shared drug class
Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for AdventHealth:

Cite this brief

Drug Landscape (2026). AdventHealth — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/adventhealth. Accessed 2026-05-16.